Answers are grounded in this paper and cite their sources.
Preclinical study reveals that muscle Car3 deficiency exacerbates myasthenia gravis via C3a-driven helper T cell activation, highlighting a critical muscle-immune communication pathway.
Myasthenia gravis is generally regarded as an autoantibody-mediated autoimmune disease, while whether myogenic factors trigger this immune disorder remains elusive. Our previous studies identified carbonic anhydrase 3 (CAR3) that is significantly downregulated in muscles from myasthenia gravis patients and plays an essential role in myasthenia gravis pathogenesis. In the present study, using experimental autoimmune myasthenia gravis (EAMG) mouse model generated with muscle specific Car3 deficient ( Acta1 cre Car3 f/f ) mice, we found that Car3 deficiency in muscle considerably exacerbated myasthenia symptoms. Importantly, EAMG Acta1 cre Car3 f/f mice exhibited substantial T follicular helper (T FH ) differentiation in muscle and significantly elevated levels of anti-AChR autoantibodies. Additionally, we detected increased intracellular complement C3a in Car3 deficient muscle cells. RNA-seq analysis and genetic validation experiments illustrated that Car3 deficiency facilitates intracellular C3a production via cathepsin S. Once released, myogenic C3a binds to C3a receptor on T cells, thereby driving T FH differentiation and subsequent autoantibody production. Collectively, our results demonstrate that Car3 deficiency promotes intracellular C3 activation in muscle cells and induces T FH differentiation, revealing a critical role of muscle-immune communication in the pathogenesis of myasthenia gravis.
No takes yet. Share an insight, caveat, or question.
Du et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: